23-Feb-2026 3:30 PM CST - Business Wire AngioDynamics to Present at the Leerink Partners Global Healthcare Conference AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the bodys vascular system, expanding cancer treatment options and improving patient quality of life, today announced, that Jim Clemmer, President and Chief Executive Officer, will present at the Leerink Partners Global Healthcare Conference on Monday, Mar. 9, 2026. The Company's presentation will begin at 1:40 p.m. (ET). A live we
6-Jan-2026 5:00 AM CST - Business Wire AngioDynamics Reports Fiscal Year 2026 Second Quarter Financial Results; Continued Double Digit Med Tech Growth Drives Increased Profitability AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the bodys vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the second quarter of fiscal year 2026, which ended November 30, 2025. Fiscal Year 2026 Second Quarter Highlights Quarter Ended November 30, 2025 Pro Forma* YoY Growth Net Sales $
23-Dec-2025 7:00 AM CST - Business Wire AngioDynamics to Report Fiscal 2026 Second Quarter Results on January 6, 2026 AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the bodys vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the second quarter of fiscal year 2026 before the market open on Tuesday, January 6, 2026. The Companys management will host a conference call at 8:00 am ET the same day to
22-Dec-2025 7:00 AM CST - Business Wire AngioDynamics to Present at the 44th Annual J.P. Morgan Healthcare Conference AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced, that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 14,
27-Oct-2025 3:30 PM CST - Business Wire AngioDynamics to Participate in the UBS Global Healthcare Conference AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced, that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the UBS Global Healthcare Conference at 8:00 a.m. ET on Monday, Nov
2-Oct-2025 5:00 AM CST - Business Wire AngioDynamics Reports Fiscal Year 2026 First Quarter Financial Results; Med Tech Growth of 26.1% Drives Continued Momentum AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the bodys vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the first quarter of fiscal year 2026, which ended August 31, 2025. Fiscal Year 2026 First Quarter Highlights Quarter Ended August 31, 2025 Pro Forma* YoY Growth Net Sales $75.7 million
18-Sep-2025 7:00 AM CST - Business Wire AngioDynamics to Report Fiscal 2026 First Quarter Results on October 2, 2025 AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the bodys vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the first quarter of fiscal year 2026 before the market open on Thursday, October 2, 2025. The Companys management will host a conference call at 8:00 am ET the same day to
6-Aug-2025 3:30 PM CST - Business Wire AngioDynamics to Present at the Canaccord Genuity 45th Annual Growth Conference AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the bodys vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the Canaccord Genuity 45th Annual Growth Conference at 9:0
15-Jul-2025 5:30 AM CST - Business Wire AngioDynamics Reports Strong Fiscal Year 2025 Fourth Quarter and Full Year Financial Results; Continued Execution Driving Accelerated, Profitable Growth AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the bodys vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the fourth quarter and fiscal year 2025, which ended May 31, 2025. Fiscal Year 2025 Fourth Quarter Highlights Quarter Ended May 31, 2025 Pro Forma* YoY Growth Pro Forma* Net Sales $80.2
Latest ANGO Trades by Congress Members
16-JUL-2025 - Debbie Wasserman Schultz, FL (District 25) sold between $1,001 and $15,000.
23-Feb-2026 3:30 PM CST - Business Wire AngioDynamics to Present at the Leerink Partners Global Healthcare Conference AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the bodys vascular system, expanding cancer treatment options and improving patient quality of life, today announced, that Jim Clemmer, President and Chief Executive Officer, will present at the Leerink Partners Global Healthcare Conference on Monday, Mar. 9, 2026. The Company's presentation will begin at 1:40 p.m. (ET). A live we
6-Jan-2026 5:00 AM CST - Business Wire AngioDynamics Reports Fiscal Year 2026 Second Quarter Financial Results; Continued Double Digit Med Tech Growth Drives Increased Profitability AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the bodys vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the second quarter of fiscal year 2026, which ended November 30, 2025. Fiscal Year 2026 Second Quarter Highlights Quarter Ended November 30, 2025 Pro Forma* YoY Growth Net Sales $
23-Dec-2025 7:00 AM CST - Business Wire AngioDynamics to Report Fiscal 2026 Second Quarter Results on January 6, 2026 AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the bodys vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the second quarter of fiscal year 2026 before the market open on Tuesday, January 6, 2026. The Companys management will host a conference call at 8:00 am ET the same day to
22-Dec-2025 7:00 AM CST - Business Wire AngioDynamics to Present at the 44th Annual J.P. Morgan Healthcare Conference AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced, that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 14,
27-Oct-2025 3:30 PM CST - Business Wire AngioDynamics to Participate in the UBS Global Healthcare Conference AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced, that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the UBS Global Healthcare Conference at 8:00 a.m. ET on Monday, Nov
2-Oct-2025 5:00 AM CST - Business Wire AngioDynamics Reports Fiscal Year 2026 First Quarter Financial Results; Med Tech Growth of 26.1% Drives Continued Momentum AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the bodys vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the first quarter of fiscal year 2026, which ended August 31, 2025. Fiscal Year 2026 First Quarter Highlights Quarter Ended August 31, 2025 Pro Forma* YoY Growth Net Sales $75.7 million
18-Sep-2025 7:00 AM CST - Business Wire AngioDynamics to Report Fiscal 2026 First Quarter Results on October 2, 2025 AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the bodys vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the first quarter of fiscal year 2026 before the market open on Thursday, October 2, 2025. The Companys management will host a conference call at 8:00 am ET the same day to
6-Aug-2025 3:30 PM CST - Business Wire AngioDynamics to Present at the Canaccord Genuity 45th Annual Growth Conference AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the bodys vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the Canaccord Genuity 45th Annual Growth Conference at 9:0
15-Jul-2025 5:30 AM CST - Business Wire AngioDynamics Reports Strong Fiscal Year 2025 Fourth Quarter and Full Year Financial Results; Continued Execution Driving Accelerated, Profitable Growth AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the bodys vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the fourth quarter and fiscal year 2025, which ended May 31, 2025. Fiscal Year 2025 Fourth Quarter Highlights Quarter Ended May 31, 2025 Pro Forma* YoY Growth Pro Forma* Net Sales $80.2
